STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION
https://doi.org/10.21518/2307-1109-2018-1-33-42
Abstract
The use of combined antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary interventions is associated with an increased risk of bleeding. In this regard, minimizing haemorrhagic risk is one of the strategic priorities in the management of this clinical group. The article is devoted to the discussion of strategies to reduce the bleeding risk in this category of patients. Particular attention is paid to the role of direct oral anticoagulants in the implementation of this strategy.
About the Author
D. A. Zateishchikov
City Clinical Hospital No 51 of Moscow Healthcare Department;
Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Valgimigli M et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2018, 39 (3): 213–260.
2. Costa F et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individualpatient datasets from clinical trials. The Lancet, 2017, 389 (10073): 1025–1034.
3. Thygesen K et al. Third universal definition of myocardial infarction. Circulation, 2012, 126 (16): 2020–35.
4. Mehran R et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv, 2011, 4 (6): 654–664.
5. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med, 1998, 338 (21): 1498–505.
6. Cannon CP et al. Oral glycoprotein IIb / IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation, 2000, 102 (2): 149–156.
7. Mahaffey KW et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation, 2011, 124 (5): 544–554.
8. Singh M. Bleeding Avoidance Strategies During Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2015, 65 (20): 2225–2238.
9. Subherwal S et al. Baseline Risk of Major Bleeding in Non – ST-Segment – Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC / AHA guidelines) Bleeding Score. Circulation, 2009, 119 (14): 1873–1882.
10. Mathews R et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry (R) – GWTG. Am J Cardiol, 2011, 107 (8): 1136–1143.
11. O’Brien EC et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European Heart Journal, 2015, 36 (46): 3258–3264.
12. Hijazi Z et al. The novel biomarker-based ABC (age, biomarkers, clinical history) – bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, 2016, 387 (10035): 2302–2311.
13. Dewilde WJM et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet, 2013, 381 (9872): 1107–1115.
14. Gibson CM et al. Prevention of Bleeding in Patient s with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375 (25): 2423–2434.
15. Cannon CP et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med, 2017, 377 (16): 1513–1524.
16. Steffel J et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist or al anticoagulants in patients with atrial fibrillation. Eur Heart J, 2018: ehy136-ehy136.
17. Eikelboom JW et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia, 2018, 120 (4): 645–656.
18. Pollack CV Jr et al. Idarucizumab for Dabigatr an Reversal – Full Cohort Analysis. N Engl J Med, 2017, 377 (5): 431–441.
Review
For citations:
Zateishchikov D.A. STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION. Aterotromboz = Atherothrombosis. 2018;(1):33-42. (In Russ.) https://doi.org/10.21518/2307-1109-2018-1-33-42
Views:
875
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 